← All trials
NCT02180568
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2014
- Primary completion
- Aug 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yonsei UniversityLead sponsor
- Yonsei UniversityOverall official - principal investigator
- Yonsei UniversityReponsible party - principal investigator
- Dankook UniversityCollaborator
- Yonsei UniversityCollaborator
- Korea UniversityCollaborator
- University of UlsanCollaborator
- Wonju Christian HospitalCollaborator
- Chung-Ang UniversityCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.